Javascript must be enabled to continue!
The Role of Immune Checkpoints in Cancer Progression
View through CrossRef
Immune checkpoint proteins are like two-faced swords that first act as gatekeepers of the immune system to protect the host from tissue damage. In contrast, these proteins can corroborate cancer progression by inhibiting tumor-specific immune responses. Here, we summarized the regulation and signaling cascade of immune checkpoints molecules (PD-1/PD-L1, CTLA-4, TIM3, TIGIT, LAG3, and BTLA), including their role in providing co-inhibitory signals for regulating T-cell response. The involvement of immune checkpoint molecules to drive cancer growth is elaborated with explanations about various anticancer strategies, such as (1) the overexpression of immune checkpoints in cancer cells, immune cells, or the surrounding environment leading to incapabilities of the tumor-specific immune response, (2) immune checkpoints interference to metabolic pathways then deplete nutrients needed by immune cells, (3) the interaction between immune checkpoints and regulatory T cells. Lastly, future challenges of immune checkpoint inhibitors are discussed briefly to get insight into their applicability in the clinical setting.
Title: The Role of Immune Checkpoints in Cancer Progression
Description:
Immune checkpoint proteins are like two-faced swords that first act as gatekeepers of the immune system to protect the host from tissue damage.
In contrast, these proteins can corroborate cancer progression by inhibiting tumor-specific immune responses.
Here, we summarized the regulation and signaling cascade of immune checkpoints molecules (PD-1/PD-L1, CTLA-4, TIM3, TIGIT, LAG3, and BTLA), including their role in providing co-inhibitory signals for regulating T-cell response.
The involvement of immune checkpoint molecules to drive cancer growth is elaborated with explanations about various anticancer strategies, such as (1) the overexpression of immune checkpoints in cancer cells, immune cells, or the surrounding environment leading to incapabilities of the tumor-specific immune response, (2) immune checkpoints interference to metabolic pathways then deplete nutrients needed by immune cells, (3) the interaction between immune checkpoints and regulatory T cells.
Lastly, future challenges of immune checkpoint inhibitors are discussed briefly to get insight into their applicability in the clinical setting.
Related Results
Cometary Physics Laboratory: spectrophotometric experiments
Cometary Physics Laboratory: spectrophotometric experiments
<p><strong><span dir="ltr" role="presentation">1. Introduction</span></strong&...
Comprehensive Analysis of M6A-Related lncRNAs, Immune Checkpoints and Immune Infiltrates in Clear Cell Renal Cell Carcinoma
Comprehensive Analysis of M6A-Related lncRNAs, Immune Checkpoints and Immune Infiltrates in Clear Cell Renal Cell Carcinoma
Abstract
Background
Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer in the world and is strongly related to the tumor immune microenvironment (TIME...
Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer
Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer
AbstractCheckpoint blockade therapy has emerged as a novel approach for cancer immunotherapy in several malignancies. However, patient prognosis and disease progression relevant to...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Defining heterogeneity in the immune infiltrate of gastroesophageal adenocarcinoma
Defining heterogeneity in the immune infiltrate of gastroesophageal adenocarcinoma
Gastro-esophageal adenocarcinoma (GEAC) is a cancer with a poor prognosis and limited treatment options. Most patients present with metastatic disease, where systemic therapies off...
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
Abstract PL02-03: Immune modulation for cancer therapy: Assessing antagonists and agonists
Abstract
The past decade has been a period of tremendous progress in the area of cancer immunotherapy. The field has progressed from a point where very modest subset...

